Significance of administration of factor Xa inhibitors after atrial fibrillation ablation

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08576
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53020:Cardiology-related
• Research Institution: University of Fukui
• Principal Investigator: Tada Hiroshi 福井大学, 学術研究院医学系部門, 教授 (70270957)
• Co-Investigator(Kenkyū-buntansha): 宮崎 晋介 福井大学, 学術研究院医学系部門, 特命准教授 (60787711)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 第Xa因子阻害薬 / 心房細動 / カテーテルアブレーション

Outline of Final Research Achievements

This study examined the significance of continued administration of an anticoagulant, factor Xa inhibitor, after catheter ablation therapy for atrial fibrillation, not only from the perspective of reducing the risk of embolism due to its anticoagulant effect, but also from the perspective of suppressing additional inflammation, atrial remodeling, and recurrent atrial fibrillation by suppressing activated blood coagulation factor X. The results of this study showed no findings suggesting an additional benefit of continued postoperative administration of factor Xa inhibitors. There was also no difference in the risk of embolic events between the discontinuation and continuation groups. We plan to increase the number of patients in the study and perform a propensity score-matched comparison between the two groups, adjusting for patient characteristics and confounding factors.

Free Research Field

不整脈

Academic Significance and Societal Importance of the Research Achievements

心房細動アブレーション後の抗凝固薬投与の適応に関しては十分なエビデンスがなく、臨床医からのニーズが非常に高いが、第Xa因子阻害薬の付加的な効果という点に着目した研究報告はない。本研究の結果は第Xa因子阻害薬の使用が抗炎症・抗リモデリング・抗動脈硬化作用を持つかどうかを臨床的に明確にでき、抗凝固薬としての薬剤のみならず、他の抗動脈硬化薬を補えるポテンシャルを持つかどうかの解明につながるものと考える。